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The American Association for Thoracic Surgery (AATS),
along with 11 other professional societies, participated in
the writing and approval of a consensus document on trans-
catheter aortic valve replacement (TAVR), which was re-
cently published in the Journal of the American College
of Cardiology in March 2012 (and also published online
in its entirety on the JTCVS and AATS Web sites). The
55-page document provides a review of the current status
of TAVR, including patient evaluation, decision making re-
garding treatment options, implantation details, postopera-
tive considerations, and future directions. The work serves
as a reference for practitioners directly involved in TAVR,
and also as a resource for the larger group of physicians
seeking to understand this technology and its role in the
treatment of aortic stenosis (AS).AORTIC STENOSIS
With the onset of symptoms, the natural history of AS is
poor. Medically managed inoperable patients in the Place-
ment of Aortic Transcatheter Valve (PARTNER) trial had
a 50% 1-year mortality rate, yet there are many patients
who are not treated because of elevated risk. Diagnosis is
generally made by echocardiography, with severe stenosis
defined as a peak velocity of greater than 4 m/s OR a valve
area of<1 cm2 when systolic function is normal (indexed
<0.6 cm2/m2). Diagnostic challenges exist in the presence
of significant aortic regurgitation, upper septal hypertrophy,
and in the failing ventricle. Patients with low gradient AS
most likely to benefit from treatment are those with contrac-
tile reserve (as shown by dobutamine infusion), limited cor-
onary disease, and a mean gradient of 20 mm Hg.OPEN SURGERY
Open surgical replacement (AVR) remains the only ef-
fective treatment considered a class I recommendation by
the ACCF/AHA guidelines in adults with severe symptom-
atic AS. Current data from the Society of Thoracic Suergons
(STS) Registry documents a mortality rate that is 2.6% forFrom Cardiac Surgery, Department of Surgery, Massachusetts General Hospital,
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comorbidity, mortality and major morbidity rates are under
1% each in many centers. Surgical AVR for most patients is
a proven low-risk therapy for AS and remains the gold
standard.
PATIENT SELECTION
Indications for treatment in AS are well established by
guidelines; however, decisions at the extreme of risk can
be complex and is facilitated by use of risk models. The
STS and logistic EuroSCORE are the most commonly
used mechanisms for mathematical estimation of surgical
risk. Along with consideration of the patient’s nonrepre-
sented risk (risk not accounted for in the models), the pa-
tient might be declared ‘‘prohibitive risk,’’ ‘‘extreme
risk,’’ or ‘‘inoperable,’’ but it is acknowledged that these
terms are used with some subjectivity.
The alternatives to surgical AVR are limited to medical
therapy and percutaneous balloon valuloplasty. Percutane-
ous balloon valuloplasty is known to often result in hemo-
dynamic improvement, but this does not translate in to
survival benefit and, as such, its role is strictly palliative
or, in rare circumstances, as a bridge toward more definitive
therapy.
TAVR BACKGROUND
In the 1990s, investigators began evaluation of stent-
based porcine bioprosthesis delivered to various aortic sites
in animal models. In 2000, a percutaneous heart valve was
placed in a child’s pulmonary arterial conduit, and in 2002,
the first human TAVR was performed. Since then, multiple
devices have been evaluated, but most human data comes
from 2 valve designs: The Sapien valve (Edwards Lifescien-
ces, Inc, Irvine, Calif) and the CoreValve (Medtronic, Inc,
Minneapolis, Minn). The Sapien is available in 23- and
26-mm sizes; the CoreValve in 23, 26, and 29 mm. The Sa-
pien valve is mounted within a balloon-expandable cobalt
chromium stent, whereas the CoreValve is self-expanding
with a nitinol frame. Initial delivery systems required 22-
or 24-French sheaths, but recent iterations have decreased
this to 18 French. Both valves are preferentially placed
via a transfermoral arteral (TF) approach. The Sapien valve
is also implantable via a transapical (TA) route, using a spe-
cialized delivery system (Ascendra; Edwards Lifesciences).
CLINICAL EVIDENCE: REGISTRIES
Initial evidence regarding the outcomes of TAVR with
Sapien and CoreValve come from registry data. The patientsery c September 2012
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a high-risk group (generally age >80 years and Euro-
SCORE>20), although there was variability and resultant
difficultly in determining whether the included patients
were truly inoperable or simply at elevated risk. Regardless,
the data showed acceptable mortality and morbidity for
both valves—30-day mortality rate ranged from 8% to
10% in most centers. Early stroke occurred at a rate of
2.5% to 5%. With both valves, patients undergoing suc-
cessful TAVR enjoyed symptom relief similar to that seen
with surgical AVR. Immediate postprocedural gradients in
TAVR valves appeared to be about 10% lower (superior)
than surgical prosthetics. There is limited information re-
garding durability beyond 5 years in registry data, but valve
failure was not observed.
EVIDENCE: PARTNER TRIAL
The PARTNER trial was a prospective, unblinded, ran-
domized, multicenter trial evaluating the safety and effec-
tiveness of the Sapien valve. Two populations were
enrolled: High-risk (cohort A; expected risk of death at 30
days, >15%), and inoperable (cohort B). Inoperability
was formally defined as ‘‘>50% predicted probability of
mortality or serious irreversible complication by 30 days 1
cardiologist and 2 surgeons.’’ Randomization was stratified
based on suitability of vascular access for TF delivery.
Cohort A patientswhowere TF candidates were randomized
to TAVR versus surgical AVR. Cohort A patients who were
not eligible for TF were randomized to TA TAVR versus
surgical AVR. Inoperable patients were randomized to
TFTAVRversusmedical therapy. Patients whowere consid-
ered inoperable butwho did not meet criteria for TF delivery
were not enrolled. Twenty-five sites participated, enrolling
699 patients in cohort A and 358 patients in cohort B.
In the inoperable patients (cohort B), TAVR was found to
substantially reduce all-cause mortality by nearly 50% at
1-year follow-up. In addition, all key secondary end points,
including patient function, significantly improved at 30
days and 1 year. TAVR was associated with an increased
risk of stroke and procedure-related adverse events suchThe Journal of Thoracic and Caas bleeding and vascular complications, but the benefit
appears to greatly exceed the risks.
In the high-risk (cohort A) patients, TAVR was noninfe-
rior to AVR for all-cause mortality at 1 year (24.2% vs
26.8%). Some morbidity was more frequent with TAVR
such as stroke (3.8% vs 2.1%) and vascular complications
(11.1% vs 3.2%). In contrast, major bleeding and atrial fi-
brillation were more common with surgical AVR. The data
support TAVR as an acceptable alternative to surgical AVR
in selected high-risk but operable patients.
PATIENT EVALUATION FOR TAVR
One of the lessons of TAVR experience has been the im-
portance of a multidisciplinary approach to the manage-
ment of patients with AS. Localization of a heart team
working together in a valve clinic will optimize communi-
cation and facilitate rapid evaluation.
In the US, only the Sapien valve is approved for use via
a TF route. Indications for clinical application should be
based on inclusion criteria used for the PARTNER trial co-
hort B (inoperable). Patients should have symptomatic AS
(New York Heart Association class 2 or greater), and docu-
mented severe AS (mean gradient >40 mm Hg or jet
velocity>4.0 m/s AND valve area<0/8 cm2 or indexed
area<0.5 cm2/m2). In addition, a cardiac interventionalist
and 2 surgeons must agree that the patient is too high
a risk for surgical AVR.
Specific exclusion criteria must be noted, in particular na-
tive annular size<18 mm or>25 mm, bicuspid aortic valve,
severe mitral regurgitation, left ventricular (LV) ejection
fraction<20%, renal failure, and estimated life expectancy
<12 months. Complex decisions regarding appropriateness
(futility) of treatment in the very frail or those with multiple
comorbidities require team discussion and consensus.
When the decision is made to consider TAVR, assessment
screening should include echocardiography and tomo-
graphic imaging. Echocardiography (transthoracic echocar-
diography or transesophageal echocardiography) must
yield a reliable measurement of annular size, generally
measured anteroposteriorly in a long-axis view. Care must
be taken to measure the true annulus and not the overlying
calcium. Overstimation of annular size can result in place-
ment of a valve that is too large with the increased risk of
incomplete expansion of the construct or catastrophic annu-
lar rupture. Underestimation can lead to increased paravalu-
lar leakage or unstable valve deployment. Additional
considerations include confirmation of a tri-leaflet valve,
presence and severity of aortic insufficiency, and relation
of the coronary arteries.
Tomographic imaging is also critical for evaluation of the
size and quality of the vascular tree. In addition to determi-
nation of adequacy of vascular dimensions, imaging
provides information on other important vascular pathology
such as the presence and location of calicification, degree ofrdiovascular Surgery c Volume 144, Number 3 535
Clinical Guidelines Agnihotritortuosity, and presence of thrombus. Multi-detector com-
puted tomography with electrocardiogram synchronization
can supplement information obtained by echocardiography
and give a comprehensive picture of root anatomy.
PROCEDURAL PERFORMANCE
The joint conduct of the procedure by the surgeon and
cardiologist is important for procedural success in
TAVR. The procedure is performed in a hybrid operating
environment, either located in the catherization laboratory
suitable converted or in a traditional operating room equip-
ped with imaging capabilities. Optimal equipment in-
cludes a state-of-the-art, large field-of-view floroscopic
imaging system—fixed overhead or floor mounted. A por-
table C-arm is not sufficient. There should be availability
of transesophageal echocardiography, general anesthesia
services, equipment for coronary intervention and open
surgery, and the ability to place the patient on cardioplu-
monary bypass, although the latter is needed in less than
5% of cases.
TAVR is typically performed under general anesthesia
with monitoring of arterial pressure, pulmonary artery pres-
sure, and transesophageal echocardiography. A temporary
pacing wire is either placed in the right ventricle from via
the central catheter or from a femoral venous route. Hypo-
thermia is avoided in a similar manner to patients undergo-
ing off-pump coronary artery bypass grafting. Patients
should be well hydrated, and inotropes are instituted when
the cardiac index is less than 1.8 L/min/m2. The mean pres-
sure should be maintained at>75 mm Hg before rapid pac-
ing to avoid the cycle of hypotension and subendocardial
ischemia than can rapidly lead to hemodynamic collapse
and fibrillation. Anticoagulation is used with a target acti-
vated clotting time of >300 seconds. Heparin may be
reversed at the completion of the procedure, although this
may be unnecessary with an uneventful percutaneous fem-
oral approach.
Both a percutaneous and cutdown approach can be used
for TF-TAVR, the former used in experienced centers for
only favorable quality femoral vessels. Once access is ob-
tained, a series of dilators is used under fluoroscopic guid-
ance, with careful attention to the resistance required. The
sheath is then passed into the body of the thoracoabdominal
aorta. Standard techniques are used to cross the aortic valve
retrograde, and a stiff wire exchange performed.
Recently, retrograde access has also been advocated via
a direct ascending aortic technique, with exposure obtained
via either an upper partial sternotomy or a small right tho-
racotomy. There is limited but encouraging experience
with auxiliary artery access as another alternative retro-
grade approach.
The TA approach is the only currently available ante-
grade approach and specialized equipment is available
only for the Sapien valve. Access is obtained via a small536 The Journal of Thoracic and Cardiovascular Surgleft thorocotomy, with a site chosen based on fluroscopic
and/or echocardiographic guidance. Removal of a small
segment of rib may avoid rib fractures and resulting pain.
Soft tissue retractors are preferred over metal retractors
for similar reasons. The pericardium is opened and the LV
apex is identified. Either purse string or mattress sutures
are placed, and a direct puncture allows passage of a guide
wire into the LVand across the aortic valve, with care taken
to avoid the mitral apparatus. Guiding catheters allow posi-
tioning in the thoracic aorta and a wire exchange is per-
formed for a stiff wire.
After a balloon valuloplasy, the replacement valve is
moved into position. Occasionally, retrograde crossing of
the heavily calcified valve can be difficult may require ad-
ditional steps such as placement of a small balloon to
prop open the native valve (buddy balloon technique).
The appropriate camera angle for viewing the aortic annu-
lus ‘‘in plane’’ is determined by root angiography. Final pre-
cise positioning is accomplished with a combination of
fluroscopy and echocardiography. Deployment then takes
place followed immediately by echocardiographic
evaluation.
COMPLICATIONS
Stoke incidence with TAVR is of concern. In the PART-
NER cohort A, the risk of clinically apparent ‘‘major’’
stroke (Rankin score  2) was 3.8% at 30 days and 5.1%
at 1 year among the TAVR group compared with 2.1%
and 2.4%, respectively, in the surgical group. In cohort B,
the stroke risk was 5% with TAVR versus 1.1% with stan-
dard therapy at 30 days and 8.4% versus 3.9% at 1 year.
TAVR may cause conduction abnormalities through me-
chanical impingement of the conduction system by the
prosthesis or displaced calcific valve. The incidence of
complete heart block requiring pacemaker implantation
has been higher with the CoreValve (19.2%-42.5%) than
the Sapien Valve (1.8%-8.5%), potentially due to its larger
profile, nitinol construction, and extension in the left ven-
tricular outflow tract. In contrast, surgical AVR pacemaker
rates are generally less than 10%.
Vascular complications are the most frequent adverse
event with TF-TAVR, with major events occurring at
a rate of 2% to 26%. Predictors include the operator expe-
rience, presence and location of vascular calcification, vas-
cular tortuosity, and sheath-to-artery ratio.
Hemodynamic collapse during the procedure or immedi-
ately after deployment can occur, often triggered by the in-
duced hypotension of rapid pacing. Specific measures must
be taken to mitigate this risk, including adequate volume
loading, minimization of rapid pacing duration, and proac-
tive anesthetic management of blood pressure. In patients
felt to be at elevated risk of collapse, cardioplumonary by-
pass may be used electively. Low-output states are common
both pre- and postdeployment and aggressively therapy isery c September 2012
Agnihotri Clinical Guidelinesindicated, including the use of inotropes and the intra-aortic
balloon pump.
Rarely, TAVR devices will be malpositioned and may
even emoblize. In the self-expanding device (CoreValve),
the construct can be moved to some degree until fully de-
ployed, but with the ballon-expandable device (Sapien),
there is only 1 opportunity to obtain the correct position.
Malpositioned valves may not function adequately (severe
aortic insufficiency) or be unstable.When unstable, a second
valve (‘‘valve-in-valve’’) may capture the first construct and
secure both to the annulus. Embolization has occurred, both
in the LVand into the aorta. The former uniformly requires
urgent surgery and the later can often be managed with de-
ployment into the thoracic aorta.
Postdeployment aortic regurgitation is usually paravalu-
lar and is common (85% of patients). Repeat ballooning
may reduce leaks and is routinely used when they are large.
At 1 year, up to 75% of patients after TAVR still have mild
or more paravalular regurgitation. Hemolysis has not been
reported but the clinical significance of paravalular leakage
is not well characterized.
Additional complications are rare and include annular
rupture, coronary occlusion, and ventricular perforation.
With the TA approach, LV disruption can occur, necessitat-
ing the use of cardioplumary bypass to facilitate attempted
repair.
FUTURE DIRECTIONS
Next-generation devices are in various stages of develop-
ment and testing and promise the potential for improve-
ments—lower profile delivery systems, more accurate
positioning, reduced paravalular leakage, and the ability
to reposition or retrieve. Many patients with dysfunction
of a conventional aortic prosthesis can be treated by
TAVR, placing the new valve within the old prosthesis
(valve-in-valve), and represent a population of active
investigation.The Journal of Thoracic and CaBased on PARTNER results, TAVR clearly has a role in
the management of the inoperable patient and it appears
to be appropriate in the very high-risk patient (STS mortal-
ity estimate>8%), but the proper application in the inter-
mediate risk (STS>4) operable patient is not yet known
and is currently under investigation (PARTNER II trial).
EUROPEAN EXPERIENCE
The European and American experiences with TAVR
have been in stark contrast because of the regulatory differ-
ences that, until recently, limited use in the US to centers
participating in national trials. In some centers, TAVR
now accounts for over 30% of AVRs. The models devel-
oped in Europe for training of TAVR centers are being rep-
licated in the US, and include didactic sessions, simulator
training, observation of cases at experience centers, and
proctoring at new centers. Monitoring of European out-
comes and usage is facilitated by use of registries and a sim-
ilar system is now in place in the US.
SUMMARYAND RECOMMENDATIONS
TAVR will undoubtedly become an increasing wide-
spread and important treatment option for patients with
AS. The recent approval of TAVR in the US allows for ex-
pansion of centers for commercial implantation. Several
recommendations can be made based on the available
evidence and current experience. This is a complex proce-
dure that requires meticulous attention to detail to avoid
complications, and the multi-specialty nature requires
a team-based approach at selected high-volume centers.
Patient selection should be based on published randomized
data: TAVR is recommended in patients with prohibitive
risk who are judged to have the potential to benefit, and
it is a reasonable option in operable patients at very high
risk. Indications are likely to evolve and encompass
additional patients. Every center should enroll patients in
a registry.rdiovascular Surgery c Volume 144, Number 3 537
